Antibody-drug conjugates

Targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin

Elisabetta Falvo, Elisa Tremante, Rocco Fraioli, Carlo Leonetti, Carlotta Zamparelli, Alberto Boffi, Veronica Morea, Pierpaolo Ceci, Patrizio Giacomini

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

A novel antibody-drug conjugate (ADC) was synthesized incorporating ferritin-based nanoparticles. An average of three molecules of monoclonal antibody (mAb) Ep1 to the human melanoma-specific antigen CSPG4 were conjugated to a single ferritin cage encapsulating about 50 cisplatin molecules (HFt-Pt-Ep1). The HFt-Pt-Ep1 nanoparticle had an estimated molecular size of about 900 kD and 33 nm, and flow cytometry demonstrated specific binding to a CSPG4+ melanoma cell line, but not to a CSPG4- breast carcinoma cell line. As compared to the cisplatin-containing ferritin nanoparticle alone (HFt-Pt), which inhibited thymidine incorporation more efficiently in breast carcinoma than melanoma cells, the mAb-derivatized HFt-Pt-Ep1 nanoparticle had a 25-fold preference for the latter. A similar preference for melanoma was observed upon systemic intravenous administration of HFt-Pt-Ep1 to nude mice xenotransplanted with pre-established, palpable melanoma and breast carcinoma tumors. Thus, we have been able to determine precise combinations and stoichiometric relationships between mAbs and nanoparticle protein cages, whereby the latter lose their tropism for ubiquitously distributed cellular receptors, and acquire instead remarkably lineage-selective binding. HFt-Pt-Ep1 is therefore an interesting model to improve the therapeutic index of antiblastic therapy in a tumor such as melanoma, which at its advanced stages is totally refractory to mono-and combination-chemotherapy.

Original languageEnglish
Pages (from-to)12278-12285
Number of pages8
JournalNanoscale
Volume5
Issue number24
DOIs
Publication statusPublished - 2013

Fingerprint

Ferritins
Antibodies
Cisplatin
Nanoparticles
Proteins
Monoclonal antibodies
Pharmaceutical Preparations
Tumors
Monoclonal Antibodies
Cells
Melanoma-Specific Antigens
Molecules
Chemotherapy
Flow cytometry
Antigens
Refractory materials
Thymidine

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Antibody-drug conjugates : Targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. / Falvo, Elisabetta; Tremante, Elisa; Fraioli, Rocco; Leonetti, Carlo; Zamparelli, Carlotta; Boffi, Alberto; Morea, Veronica; Ceci, Pierpaolo; Giacomini, Patrizio.

In: Nanoscale, Vol. 5, No. 24, 2013, p. 12278-12285.

Research output: Contribution to journalArticle

Falvo, Elisabetta ; Tremante, Elisa ; Fraioli, Rocco ; Leonetti, Carlo ; Zamparelli, Carlotta ; Boffi, Alberto ; Morea, Veronica ; Ceci, Pierpaolo ; Giacomini, Patrizio. / Antibody-drug conjugates : Targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. In: Nanoscale. 2013 ; Vol. 5, No. 24. pp. 12278-12285.
@article{e4b7be3db71947ba870d50345586bb19,
title = "Antibody-drug conjugates: Targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin",
abstract = "A novel antibody-drug conjugate (ADC) was synthesized incorporating ferritin-based nanoparticles. An average of three molecules of monoclonal antibody (mAb) Ep1 to the human melanoma-specific antigen CSPG4 were conjugated to a single ferritin cage encapsulating about 50 cisplatin molecules (HFt-Pt-Ep1). The HFt-Pt-Ep1 nanoparticle had an estimated molecular size of about 900 kD and 33 nm, and flow cytometry demonstrated specific binding to a CSPG4+ melanoma cell line, but not to a CSPG4- breast carcinoma cell line. As compared to the cisplatin-containing ferritin nanoparticle alone (HFt-Pt), which inhibited thymidine incorporation more efficiently in breast carcinoma than melanoma cells, the mAb-derivatized HFt-Pt-Ep1 nanoparticle had a 25-fold preference for the latter. A similar preference for melanoma was observed upon systemic intravenous administration of HFt-Pt-Ep1 to nude mice xenotransplanted with pre-established, palpable melanoma and breast carcinoma tumors. Thus, we have been able to determine precise combinations and stoichiometric relationships between mAbs and nanoparticle protein cages, whereby the latter lose their tropism for ubiquitously distributed cellular receptors, and acquire instead remarkably lineage-selective binding. HFt-Pt-Ep1 is therefore an interesting model to improve the therapeutic index of antiblastic therapy in a tumor such as melanoma, which at its advanced stages is totally refractory to mono-and combination-chemotherapy.",
author = "Elisabetta Falvo and Elisa Tremante and Rocco Fraioli and Carlo Leonetti and Carlotta Zamparelli and Alberto Boffi and Veronica Morea and Pierpaolo Ceci and Patrizio Giacomini",
year = "2013",
doi = "10.1039/c3nr04268e",
language = "English",
volume = "5",
pages = "12278--12285",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "24",

}

TY - JOUR

T1 - Antibody-drug conjugates

T2 - Targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin

AU - Falvo, Elisabetta

AU - Tremante, Elisa

AU - Fraioli, Rocco

AU - Leonetti, Carlo

AU - Zamparelli, Carlotta

AU - Boffi, Alberto

AU - Morea, Veronica

AU - Ceci, Pierpaolo

AU - Giacomini, Patrizio

PY - 2013

Y1 - 2013

N2 - A novel antibody-drug conjugate (ADC) was synthesized incorporating ferritin-based nanoparticles. An average of three molecules of monoclonal antibody (mAb) Ep1 to the human melanoma-specific antigen CSPG4 were conjugated to a single ferritin cage encapsulating about 50 cisplatin molecules (HFt-Pt-Ep1). The HFt-Pt-Ep1 nanoparticle had an estimated molecular size of about 900 kD and 33 nm, and flow cytometry demonstrated specific binding to a CSPG4+ melanoma cell line, but not to a CSPG4- breast carcinoma cell line. As compared to the cisplatin-containing ferritin nanoparticle alone (HFt-Pt), which inhibited thymidine incorporation more efficiently in breast carcinoma than melanoma cells, the mAb-derivatized HFt-Pt-Ep1 nanoparticle had a 25-fold preference for the latter. A similar preference for melanoma was observed upon systemic intravenous administration of HFt-Pt-Ep1 to nude mice xenotransplanted with pre-established, palpable melanoma and breast carcinoma tumors. Thus, we have been able to determine precise combinations and stoichiometric relationships between mAbs and nanoparticle protein cages, whereby the latter lose their tropism for ubiquitously distributed cellular receptors, and acquire instead remarkably lineage-selective binding. HFt-Pt-Ep1 is therefore an interesting model to improve the therapeutic index of antiblastic therapy in a tumor such as melanoma, which at its advanced stages is totally refractory to mono-and combination-chemotherapy.

AB - A novel antibody-drug conjugate (ADC) was synthesized incorporating ferritin-based nanoparticles. An average of three molecules of monoclonal antibody (mAb) Ep1 to the human melanoma-specific antigen CSPG4 were conjugated to a single ferritin cage encapsulating about 50 cisplatin molecules (HFt-Pt-Ep1). The HFt-Pt-Ep1 nanoparticle had an estimated molecular size of about 900 kD and 33 nm, and flow cytometry demonstrated specific binding to a CSPG4+ melanoma cell line, but not to a CSPG4- breast carcinoma cell line. As compared to the cisplatin-containing ferritin nanoparticle alone (HFt-Pt), which inhibited thymidine incorporation more efficiently in breast carcinoma than melanoma cells, the mAb-derivatized HFt-Pt-Ep1 nanoparticle had a 25-fold preference for the latter. A similar preference for melanoma was observed upon systemic intravenous administration of HFt-Pt-Ep1 to nude mice xenotransplanted with pre-established, palpable melanoma and breast carcinoma tumors. Thus, we have been able to determine precise combinations and stoichiometric relationships between mAbs and nanoparticle protein cages, whereby the latter lose their tropism for ubiquitously distributed cellular receptors, and acquire instead remarkably lineage-selective binding. HFt-Pt-Ep1 is therefore an interesting model to improve the therapeutic index of antiblastic therapy in a tumor such as melanoma, which at its advanced stages is totally refractory to mono-and combination-chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84888377519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888377519&partnerID=8YFLogxK

U2 - 10.1039/c3nr04268e

DO - 10.1039/c3nr04268e

M3 - Article

VL - 5

SP - 12278

EP - 12285

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 24

ER -